News All News

Scaling biomanufacturing is often constrained by how efficiently gases move through liquids—FluxBio, a Harvard startup out of the lab of Jarad Mason in the Department of Chemistry & Chemical Biology at Harvard, found a solution by re-engineering the liquid, not the machine. The microporous water technology received critical early support from the Blavatnik Biomedical Accelerator to advance while in the lab and ultimately form the basis for FluxBio.

Harvard Magazine’s Q&A with Leonardo Riella, the HMS Harold and Ellen Danser Associate Professor of Surgery at Massachusetts General Hospital, on the advancement of xenotransplantation. Reilla discusses what the research and medical teams learned from the first successful kidney transplant using a genetically engineered pig kidney developed by eGenesis, a company founded by HMS Professor George Church and former HMS postdoctoral fellow Luhan Yang with support from the Wyss Institute.

Attivare, a startup advancing a portfolio of technologies developed at the Wyss Institute, John A. Paulson School of Engineering and Applied Sciences, Dana-Farber Cancer Institute, and Massachusetts General Hospital, has shown promising results in cancer clinical trials and is developing a malaria vaccine. Through decades of innovation and cross-disciplinary collaboration, the technology has the potential to fight cancer more effectively or prevent pathogen-related infections. 

Harvard University has expanded a research alliance agreement with Northpond Labs to fund translational research, accelerate commercialization, and advance breakthrough healthcare innovations across Harvard labs at the Wyss Institute, Harvard Medical School, John A. Paulson School of Engineering and Applied Sciences, and Faculty of Arts and Sciences.